Crinetics Pharmaceuticals, Inc. (CRNX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Crinetics (CRNX) Q1 2026: Palsonify Achieves 70% Reimbursement, Broadening Acromegaly Market Penetration
May 08, 2026
-
Crinetics (CRNX) Q4 2025: $1.4B Cash Position Extends Runway for Pipeline and Pelsonify Launch
February 27, 2026
-
Crinetics (CRNX) Q3 2025: 70% of Early Palsonify Scripts from Community Docs Signals Broad Uptake Path
November 07, 2025
-
Crinetics (CRNX) Q2 2025: $1.2B Cash Runway Secured as Palsonify Launch Nears FDA Decision
August 08, 2025
-
Crinetics (CRNX) Q1 2025: R&D Spend Jumps 43% as Paltusotine Launch Nears, Pipeline Push Accelerates
July 05, 2025